CUSIP: 05370A108
Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
150,858,761
-
Total 13F shares
-
44,395,070
-
Share change
-
+9,785,864
-
Total reported value
-
$1,093,343,381
-
Price per share
-
$24.63
-
Number of holders
-
108
-
Value change
-
+$240,851,131
-
Number of buys
-
66
-
Number of sells
-
27
Quarterly Holders Quick Answers
What is CUSIP 05370A108?
CUSIP 05370A108 identifies RNA - Atrium Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2021
-
Previous quarter:
Q2 2021
Recent filing periods for CUSIP 05370A108:
Institutional Holders of Atrium Therapeutics, Inc. - Common Stock (RNA) as of Q3 2021
As of 30 Sep 2021,
Atrium Therapeutics, Inc. - Common Stock (RNA) was held by
108 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
44,395,070 shares.
The largest 10 holders included
PRICE T ROWE ASSOCIATES INC /MD/, RTW INVESTMENTS, LP, FMR LLC, BlackRock Inc., EcoR1 Capital, LLC, FEDERATED HERMES, INC., Cormorant Asset Management, LP, VANGUARD GROUP INC, Avidity Partners Management LP, and STATE STREET CORP.
This page lists
108
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.